104795-11-1Relevant articles and documents
CONFORMATIONALLY CONSTRAINED MACROCYCLIC COMPOUNDS
-
Page/Page column 43, (2017/05/02)
Conformationally constrained macrocyclic compounds of formula (I), including substituents E with at least one ester moiety, G and Q, as defined in the description and the claims, and salts thereof, can be metabolized to compounds that have the property to
Process Development and Synthesis of Birinapant: Large Scale Preparation and Acid-Mediated Dimerization of the Key Indole Intermediate
Deng, Yijun,Xie, Qiuzhe,LaPorte, Matthew G.,Chasnoff, Anna T. A.,Mortensen, Mark A.,Patra, Debasis,Putrelo, Seth A.,Antonovich, Robert S.,Cao, Hong,Yan, Jun,Cooper, Arthur J.,Rippin, Susan R.,Alexander, Matthew D.,Kumar, Pavan Tirunahari,Hendi, Mukta S.,Lee, Yu-Hua,Haimowitz, Thomas,Condon, Stephen M.
, p. 242 - 252 (2016/03/04)
Birinapant/TL32711 (1) is a novel bivalent antagonist of the inhibitor of apoptosis (IAP) family of proteins which is currently in clinical development for the treatment of cancer and hepatitis B virus (HBV) infection. In this report, we present a detaile
3-pyrrolidinylthio-1-azabicyclo(3.2.0)-hept-2-ene-2-carboxylic acid compounds and antimicrobial activity thereof
-
, (2008/06/13)
This invention consists of 3-pyrrolidinylthio-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid compounds and their use as antimicrobial agents in the treatment of infectious diseases.